Compounds > valine

valine and imatinib mesylate

valine has been researched along with imatinib mesylate in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brownlow, N; Dibb, NJ; Domin, J; Taylor, JR1
Boshoff, C; Frow, R; Gana-Weisz, M; Hartzoulakis, B; McLean, SR; Selwood, D; Whelan, J1
Hervé, F; Marie, I1
Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ1
Cheong, JW; Choi, JR; Kim, SJ; Lee, KA; Lee, KW; Park, TS; Song, J; Song, S; Suh, B1
Bay, JO; Berger, MG; Chaleteix, C; Fleury, J; Gouas, L; Goumy, C; Ledoux-Pilon, A; Richard-Pebrel, C; Tchirkov, A; Tournilhac, O; Vago, P; Véronèse, L1
Blombery, P; Lade, S; Prince, HM; Wong, SQ1

Reviews

1 review(s) available for valine and imatinib mesylate

ArticleYear
[Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
    La Revue de medecine interne, 2006, Volume: 27, Issue:6

    Topics: Amino Acid Substitution; Benzamides; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; Janus Kinase 2; Phenylalanine; Piperazines; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Valine

2006

Other Studies

6 other study(ies) available for valine and imatinib mesylate

ArticleYear
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
    Oncogene, 2006, Jan-05, Volume: 25, Issue:1

    Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Inhibitory Concentration 50; Macrophage Colony-Stimulating Factor; Mice; Mutation; Neoplasms; Oncogene Protein v-cbl; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Time Factors; Valine

2006
Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:12

    Topics: Alanine; Alleles; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Piperazines; Pyrimidines; Sequence Homology, Amino Acid; Stem Cell Factor; Valine

2005
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
    The Journal of clinical investigation, 2007, Volume: 117, Issue:9

    Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine

2007
Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
    Cancer genetics and cytogenetics, 2009, Apr-01, Volume: 190, Issue:1

    Topics: Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 3; Drug Resistance, Neoplasm; Female; Glutamic Acid; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic; Trisomy; Valine

2009
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Phenylalanine; Piperazines; Pyrimidines; Thrombocytosis; Valine

2010
Erdheim-Chester disease harboring the BRAF V600E mutation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Erdheim-Chester Disease; Glutamic Acid; Humans; Imatinib Mesylate; Immunohistochemistry; Interferon-alpha; Male; Middle Aged; Mutation; Piperazines; Prednisolone; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Valine

2012